Please note that following on from information provided to NICE by the company in May 2020, the appraisal of ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1025 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in May 2020, the appraisal of ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 May 2020 | Suspended. Topic has been suspended |
| 02 February 2018 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual